Views & Analysis Behind the buzz of real-world data and real-world evidence Putting the who, where and why of real-world studies into context.
News NICE ‘pauses’ plans to introduce charges for pharma Plans by NICE to start charging pharma companies for appraising their medicines are to be ‘paused’ in order to allow the government to complete its life sciences strategy.
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Views & Analysis The budget impact of new medicines What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
